Crown Bioscience LogoCrown Bioscience, a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, has reached a milestone in developing a model of non-alcoholic fatty liver disease (NAFLD).

The new NAFLD model was created by PreClinOmics, a Crown Bioscience company specializing in contract preclinical services for metabolic, cardiovascular and renal diseases, using its proprietary FATZO model for obesity and type 2 diabetes. The FATZO model is a spontaneously hyperglycaemic model and serves as an excellent translational platform for developing models of NAFLD.

“The new model complements our NHP model of NAFLD and non-alcoholic steatohepatitis (NASH), creating a continuum of in vivo platforms that enables us to provide our clients with end-to-end preclinical support for their CVMD research,” said Jim Wang, MD, Senior Vice President of cardiovascular and metabolic disease (CVMD) research at CrownBio. “It can be used as a translational tool to study novel compounds in late stage drug discovery.”

CrownBio will be presenting data on this new model at the upcoming Discovery on Target meeting in Boston (MA, USA). Amar Thyagarajan, PhD, Associate Director of product marketing and strategy at CrownBio, will give a presentation titled “Advances in Preclinical Models for Cardio-Metabolic and Liver Disease” at 3:15 PM on 20 September.

“Presently, there are no approved therapies for NASH,” said Van Jackson, PhD, general manager and CSO at PreClinOmics. “In its most severe form, NASH disease can lead to liver cancer and the need for transplantation. We are hopeful this new research model can be used as a translational model for NASH and lead to new avenues for treatment and recovery.”